PHILIPPINE CONSULATE VISITS LIVERITAS BIOSCIENCES LABORATORY IN SOUTH SAN FRANCISCO
Consul General Neil Frank Ferrer (third from right), Consul Rowena R. Pangilinan-Daquipil (second from right), and Trade Commissioner Anne Marie Kristine Umali (rightmost) pose with Dr. Lieza Danan (third from left), Mr. Kenneth Co (second from left) and Mr. Eric Webostad (leftmost) (San Francisco PCG photo)
SOUTH SAN FRANCISCO, California — The Philippine Consulate General in San Francisco, led by Consul General Neil Frank R. Ferrer, visited LiVeritas Biosciences Laboratory on 6 August 2025 to learn more about the company’s pioneering use of artificial intelligence (AI) in accelerating drug development, and to explore possible collaboration opportunities in the Philippines.
The Consulate takes pride in the fact that LiVeritas was co-founded by a Filipina, Dr. Lieza Danan, who serves as the company’s Chief Executive Officer. Joining Dr. Danan were Co-Founder and Legal & Intellectual Property Strategy Officer Mr. Eric Webostad, and Late-Stage Development CMC Manufacturing & Supply Chain Officer Mr. Kenneth Co. Consul General Ferrer was accompanied by Consul and Economic Officer Rowena Pangilinan-Daquipil, Trade Commissioner Anne Marie Kristine Umali and Economic Assistant Danica Vismonte.
Founded in 2021 by Dr. Danan, Mr. Webostad, and three Filipino professionals (a software engineer, a data analyst, and a data scientist), LiVeritas has developed proprietary AI-driven “digital scientist” tools that streamline the traditionally fragmented drug development process. These tools have already reduced clinical testing timelines from four weeks to just five days, with plans to shorten this further to under three days within the next quarter.
Specializing in Chemistry, Manufacturing, and Controls (CMC) analytics, LiVeritas integrates all data workflows into a single FDA-compliant operating system, removing inefficiencies and enabling faster submission of Investigational New Drug (IND) applications.
LiVeritas aims to expand its proprietary AI tools as well as increase its digital scientists within the next three years. While LiVeritas currently serves clients exclusively in the U.S., the company is open to exploring opportunities in the Philippines. The Consulate expressed readiness to support this endeavor. END
Dr. Lieza Danan showcases a high-precision mass spectrometer, a key instrument used by LiVeritas to analyze molecular properties in drug development (San Francisco PCG photo)
Mr. Eric Webostad explains how LiVeritas leverages Agentic AI to amplify scientific productivity and streamline drug development processes (San Francisco PCG photo)